Home Conditions A–Z Papilledema and idiopathic intracranial hypertension (IIH)

Papilledema and idiopathic intracranial hypertension (IIH)

Optic nerve swelling from raised pressure around the brain

Reviewed by Dr. James Deom, OD, MPH, FAAO, FSLS, Chief of Eye Care Services, Hazleton Eye Specialists Last reviewed: November 12, 2026 Audience: All (patient and clinician sections)

Same-day care

Sudden vision loss in one eye needs same-day care.

Call an eye doctor or go to the emergency department.

Call the office 570-453-2020 Find an eye doctor 5 offices Schedule an exam Pick your office

For patients and families

What it is

Papilledema is swelling of both optic nerves caused by raised pressure in the fluid around the brain. It always needs prompt testing to find the cause.¹ One cause is idiopathic intracranial hypertension (IIH), sometimes called pseudotumor cerebri. IIH most often affects women of childbearing age with obesity or recent weight gain, although anyone can develop it.² ³

Symptoms

Headaches, often daily
Brief graying or blacking out of vision for seconds, sometimes when standing up
A whooshing sound in the ears in time with your heartbeat (pulsatile tinnitus)
Double vision
Some people have no symptoms, and swelling is found at a routine eye exam

Why it matters

If pressure stays high, the optic nerves can be permanently damaged and side vision lost.³ Most people do well with timely treatment and follow-up.

Testing and treatment

Testing usually includes an MRI of the brain with a scan of the veins (MRV) and a lumbar puncture (spinal tap) to measure pressure.¹ Treatment often includes weight loss when weight is a factor, medicine such as acetazolamide, and, if vision is at risk, surgery or other procedures.² ⁴ ⁵ Some medicines, including certain antibiotics (tetracyclines) and high doses of vitamin A or related acne medicines, have been linked to raised pressure, so bring a full list of your medicines.¹

GLP-1 medicines and IIH

Because sustained weight loss is part of IIH treatment, researchers are studying GLP-1 medicines in IIH. A small trial of exenatide (a GLP-1 medicine) lowered brain pressure in women with IIH.⁶ GLP-1 medicines are not approved by the FDA to treat IIH, and larger trials are needed. If you have IIH and take a GLP-1 medicine, keep your eye and neurology follow-ups.

Dr. Deom’s recommendation (clinical opinion / practice recommendation)

Dr. James Deom recommends that everyone starting or taking a GLP-1 medication have a comprehensive dilated eye exam with OCT, OCT angiography (OCTA), and retinal photography (fundus photos with autofluorescence) as a baseline and for follow-up, and seek same-day care for sudden vision loss.

This is his clinical opinion, not a formal rule from every professional group. AAO and NANOS do not recommend an eye exam only to predict NAION, and no test can reliably predict or prevent it. Dr. Deom recommends the baseline so there is a record to compare against if anything changes, and so other eye problems can be found early.

Dr. James Deom’s personal clinical thought

This is his opinion, not established evidence. It is not a finding from the studies or a position of the FDA, EMA, AAO, NANOS, or AOA.

As people lose weight and get healthier on GLP-1 medicines, their blood pressure and cholesterol medicines are often not reviewed or adjusted. Blood pressure treatment that is no longer matched to a person’s needs may lead to low blood pressure (hypotension). Low blood pressure can be more pronounced at night and could reduce blood flow to the optic nerve during sleep. That possibility would fit the typical way NAION presents: vision loss noticed on waking.

Dr. Deom recommends that people taking a GLP-1 medicine also work on exercise and diet, and keep regular visits with their usual doctors — even if that doctor did not prescribe the GLP-1 — so the rest of their care, including blood pressure, is maintained. Do not start, stop, or change a blood pressure or cholesterol medicine on your own; talk with the clinician who prescribes it.

Prescribers: see Papilledema and IIH in patients on GLP-1 medicines.

For clinicians

Bilateral disc edema is papilledema until proven otherwise and requires urgent neuro-imaging (MRI with contrast and MR venography) to exclude mass lesion and cerebral venous sinus thrombosis, followed by lumbar puncture with opening pressure and CSF analysis.¹
Diagnostic criteria (Friedman 2013): papilledema, normal neurologic exam except cranial nerve abnormalities, normal brain parenchyma without hydrocephalus, mass, or structural lesion, normal CSF composition, and elevated LP opening pressure (≥25 cm CSF in adults).¹ Criteria also address diagnosis without papilledema.
Treatment: the IIH Treatment Trial showed that acetazolamide plus a low-sodium weight-reduction diet improved visual field function compared with diet alone in mild visual loss.⁴ The IIH:WT trial found bariatric surgery lowered ICP more than a community weight-management program at 12 months.⁵ UK consensus guidelines outline management, including surgical options for threatened vision.²
Monitoring: visual fields, acuity, OCT RNFL (and GCL to distinguish recovery from atrophy), and fundus photographs.² ³
Pseudopapilledema: optic disc drusen and crowded discs can mimic papilledema; EDI-OCT and fundus autofluorescence help (see Optic disc drusen).
GLP-1 RA evidence: exenatide lowered ICP in a 16-patient randomized trial with telemetric monitoring.⁶ This supports further study, not routine off-label use for IIH.

Dr. Deom’s recommendation (clinical opinion / practice recommendation)

This is his clinical opinion and practice recommendation, not a society mandate. AAO and NANOS do not recommend routine examination solely to predict NAION, and no exam or imaging test reliably predicts or prevents an acute event. The baseline is intended to document disc anatomy and retinal status for later comparison and to detect other eye disease. See the study comparison for where professional positions agree and differ.

Dr. James Deom’s personal clinical thought

This is his opinion, not established evidence. It is not a finding from the studies or a position of the FDA, EMA, AAO, NANOS, or AOA.

As patients lose weight and their overall health improves on GLP-1 medicines, blood pressure and cholesterol medicines are often not re-addressed. Over-treatment of blood pressure may lead to hypotension, which can worsen at night and could cause nighttime hypoperfusion of the optic nerve. That sequence would fit the typical presentation of NAION (vision loss noticed on waking).

He recommends that people on GLP-1 medicines also improve exercise and diet, and keep regular visits with their usual doctors, even if that clinician did not prescribe the GLP-1, so the rest of their care, including blood pressure, is maintained.

For prescribers: consider reviewing antihypertensive dosing and timing (including bedtime dosing) as weight drops. Coordinate changes with the patient’s usual clinician when someone else wrote the GLP-1 prescription.

How to reach us

Same-day evaluation: providers can call the office at 570-453-2020 (fax 570-453-1020), or refer a patient or ask a question by email. Patients can schedule an exam online.

For privacy, please don’t include patient names or other identifying details in email. Our team will call to schedule and gather details securely.

General contact and referrals: Hazleton Eye Specialists, phone 570-453-2020, fax 570-453-1020. See Referral information for what to send.

References

Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159-1165. https://pubmed.ncbi.nlm.nih.gov/23966248/
Mollan SP, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088-1100. https://pubmed.ncbi.nlm.nih.gov/29903905/
American Academy of Ophthalmology. What Is Idiopathic Intracranial Hypertension? https://www.aao.org/eye-health/diseases/what-is-idiopathic-intracranial-hypertension
NORDIC IIH Study Group Writing Committee. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the IIH Treatment Trial. JAMA. 2014;311(16):1641-1651. https://pubmed.ncbi.nlm.nih.gov/24756514/
Mollan SP, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurol. 2021;78(6):678-686. https://pubmed.ncbi.nlm.nih.gov/33900360/
Mitchell JL, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821-1830. https://pubmed.ncbi.nlm.nih.gov/36907221/

How to reach us

Hazleton Eye Specialists: phone 570-453-2020, fax 570-453-1020. Addresses for all five offices (Hazleton, Stroudsburg, Nanticoke, Pottsville, and Bangor) are on Find an Eye Doctor.

Sudden vision loss needs same-day care. Call an eye doctor right away. If you also have a new headache, jaw pain when chewing, scalp tenderness, fever, or you are over 50 and feel unwell, go to the emergency department.

Medical disclaimer. This page is for general education. The patient section is not medical advice, and the clinician section is not a clinical practice guideline; neither replaces an examination, clinical judgment, or specialty consultation. If you have sudden vision loss, seek same-day care from an eye doctor or an emergency department. Information is current as of the “last reviewed” date.